In the past few years we have learned more about the pathophysiology, and the immunological mechanisms of psoriasis. This knowledge has further been translated into novel biologic treatments that have new mechanisms of action. The most recent innovations are the interleukin-23 inhibitors.1 As a result of this progress in science and technology, dermatologists now have more treatment options for patients with psoriasis compared to the past.
Dr. Kim Papp from Canada, who is a one of the top dermatologists in the world specializing in psoriasis, has contributed to clinical development of most biologic psoriasis treatments (read more here). Janssen recently interviewed Dr. Kim Papp and asked what the new treatment options mean for dermatologists and especially for patients.
How to choose a biologic treatment?
Psoriasis is a complex disease with skin symptoms that are often accompanied with various co-morbidities.2 What are the patient characteristics and factors that Dr. Kim Papp considers when choosing the optimal treatment choice for his patients?
Why aim for clear skin? Efficacy from the patient perspective
New biologic treatments have increased the expectations on treatment efficacy. Research also shows that high treatment response on skin correlates with improvements in quality of life. 3 But what does this mean in clinical practice, and what are Dr. Kim Papp’s treatment goals for psoriasis patients?